Nektar Therapeutics' (NKTR) "Buy" Rating Reaffirmed at HC Wainwright

Key Points

• HC Wainwright reaffirmed a “Buy” rating on Nektar Therapeutics with a $185 price target, implying 293.7% potential upside; analysts overall maintain a “Moderate Buy” consensus with an average target of $138.50.
• Nektar’s rezpegaldesleukin showed durable responses in Phase 2b studies for alopecia areata and atopic dermatitis, while the company expanded its late-stage development plans with another Phase 3 study.
• The company remains financially challenged, reporting a $1.23 quarterly loss per share, a negative 287.84% net margin, and projected full-year losses of $8.16 per share; the stock opened at $46.99, well below its analyst targets.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report)'s stock had its "buy" rating reissued by analysts at HC Wainwright in a report released on Friday, Benzinga reports. They currently have a $185.00 price target on the biopharmaceutical company's stock. HC Wainwright's price objective would suggest a potential upside of 293.70% from the company's current price.

Several other equities research analysts have also weighed in on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Nektar Therapeutics in a research note on Friday, August 28th. JPMorgan Chase & Co. initiated coverage on Nektar Therapeutics in a research note on Friday, August 21st. They issued a "neutral" rating and a $65.00 target price for the company. TD Cowen raised Nektar Therapeutics to a "strong-buy" rating in a report on Monday, August 24th. Canaccord Genuity Group began coverage on shares of Nektar Therapeutics in a research report on Wednesday, July 22nd. They set a "buy" rating and a $153.00 price target for the company. Finally, BTIG Research reaffirmed a "buy" rating and issued a $178.00 price target on shares of Nektar Therapeutics in a research note on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $138.50.

Nektar Therapeutics Price Performance

Shares of NKTR stock opened at $46.99 on Friday. The stock has a market cap of $1.60 billion, a P/E ratio of -7.01 and a beta of 1.26. Nektar Therapeutics has a one year low of $33.40 and a one year high of $109.00. The stock has a fifty day moving average price of $70.09 and a 200 day moving average price of $71.25.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($1.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.97) by $0.74. Nektar Therapeutics had a negative net margin of 287.84% and a negative return on equity of 37.87%. The firm had revenue of $10.13 million for the quarter, compared to analyst estimates of $10.43 million. Equities research analysts anticipate that Nektar Therapeutics will post -8.16 EPS for the current year.

Insider Activity at Nektar Therapeutics

In other news, CEO Howard Robin sold 418 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $71.98, for a total value of $30,087.64. Following the completion of the sale, the chief executive officer owned 54,627 shares of the company's stock, valued at approximately $3,932,051.46. This represents a 0.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.50% of the company's stock.

Institutional Investors Weigh In On Nektar Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. KBC Group NV bought a new position in Nektar Therapeutics during the first quarter worth about $52,000. State of Wyoming acquired a new position in shares of Nektar Therapeutics during the 1st quarter worth approximately $67,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Nektar Therapeutics during the 1st quarter worth approximately $209,000. Great Lakes Advisors LLC acquired a new stake in Nektar Therapeutics during the 2nd quarter valued at $206,000. Finally, Pale Fire Capital SE acquired a new stake in Nektar Therapeutics during the 2nd quarter valued at $234,000. 75.88% of the stock is owned by institutional investors.

Key Nektar Therapeutics News

Here are the key news stories impacting Nektar Therapeutics this week:

• Positive Sentiment: New Phase 2b data showed durable responses for rezpegaldesleukin in severe alopecia areata and atopic dermatitis. In alopecia areata, 75% of responders maintained a SALT score of 20 or lower four months after treatment ended, while 63% maintained that response after six months. Hair regrowth also continued after treatment. New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement
• Positive Sentiment: Nektar initiated a third Phase 3 study in treatment-experienced atopic dermatitis patients and plans to begin the Phase 3 ZENITH-AA alopecia areata study in early 2027, expanding the potential commercial opportunity for rezpegaldesleukin. Nektar Therapeutics Shareholder and Analyst Call
• Positive Sentiment: Separate biomarker results showed that rezpegaldesleukin affected multiple immune pathways as early as Week 2, with molecular changes significantly associated with later clinical improvement. This supports the drug’s proposed regulatory T-cell mechanism. New Biomarker Data for Rezpegaldesleukin
• Neutral Sentiment: Analyst coverage lists a consensus price target of $138.50, but the target remains dependent on successful late-stage development and regulatory progress. Nektar Consensus Target Price
• Negative Sentiment: The stock fell as investors reacted to the new mid-stage alopecia data. Although the results were positive, the data may not have provided a sufficiently strong near-term catalyst to offset uncertainty over Phase 3 execution, approval prospects, commercialization, and Nektar’s continuing losses. Elevated options activity also reflects unusually high volatility and bearish positioning. Nektar Drops After Mid-Stage Hair Loss Data

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing medicines that use the body's immune system to treat cancer and autoimmune diseases. The company's research programs are based on proprietary drug-design and immunology technologies intended to improve the activity, targeting, or dosing of therapeutic agents.

Nektar's pipeline has included NKTR-255, an investigational interleukin-15 receptor agonist designed to activate natural killer cells and support antitumor immune responses.